by barry-jtcir | Jan 26, 2024 | Press Releases
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
by barry-jtcir | Dec 5, 2023 | Press Releases
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival1 LA JOLLA, CA,...
by barry-jtcir | Nov 27, 2023 | Press Releases
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited...
by barry-jtcir | Nov 15, 2023 | Press Releases
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are limited with only two approved drugs that come with significant...
by barry-jtcir | Oct 31, 2023 | Press Releases
Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release,...
